Amgen psoriasis drug tops J&J's Stelara in Phase III study(Reuters) - Amgen Inc said on Tuesday that its experimental psoriasis drug, brodalumab, met all the goals of a late-stage study, clearing the rough skin patches associated with the disease more thoroughly than Johnson & Johnson's Stelara and a placebo. Amgen is developing brodalumab under a multi-drug collaboration with AstraZeneca that involves splitting costs and eventual profits. After 12 weeks of treatment of 1,881 patients with moderate to severe plaque psoriasis, 36. ...
Source: Amgen psoriasis drug tops J&J's Stelara in Phase III study (http://news.yahoo.com/amgen-psoriasis-drug-tops-j-js-stelara-phase-215419585--finance.html)